|
|
LT(R192G) |
|
Vaxjo ID |
379 |
|
Vaccine Adjuvant Name |
LT(R192G) |
|
Adjuvant VO ID |
VO_0005528
|
|
Description |
microorganism derived adjuvant that induces mixed Th1/Th2 response |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
heat-labile toxin derived from a clone of E. coil JM 83 |
|
Structure |
mutation of wild type LT of arginine 192 to glycine |
|
Preparation |
final product was lyophilized in vials containing 1,000 µg of protein per vial |
|
Dosage |
2 µg |
|
Function |
enhances DC activation, cytokine secretion |
| References |
Lu et al., 2002: Lu X, Clements JD, Katz JM. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine. 2002; 20(7-8); 1019-1029. [PubMed: 11803061].
NCT00090688: Clinicaltrials.gov [https://www.clinicaltrials.gov/study/NCT00090688]
Riddle et al., 2020: Riddle MS, Maciel M Jr, Porter CK, Poole ST, Gutierrez RL, Gormley R, Laird RM, Sebeny PJ, Dori KE, Greenleaf ME, Hoq F, Turiansky GW, Jarell A, Hawk D, Tribble D, Savarino SJ. A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G. Vaccine. 2020; 38(45); 7040-7048. [PubMed: 32978003].
|
|
